Last reviewed · How we verify
Nifekalant hydrochloride — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Nifekalant hydrochloride (Nifekalant hydrochloride) — Sichuan Baili Pharmaceutical Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Nifekalant hydrochloride TARGET | Nifekalant hydrochloride | Sichuan Baili Pharmaceutical Co., Ltd. | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Nifekalant hydrochloride CI watch — RSS
- Nifekalant hydrochloride CI watch — Atom
- Nifekalant hydrochloride CI watch — JSON
- Nifekalant hydrochloride alone — RSS
Cite this brief
Drug Landscape (2026). Nifekalant hydrochloride — Competitive Intelligence Brief. https://druglandscape.com/ci/nifekalant-hydrochloride. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab